Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also i...
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.
- Conditions
- Interventions
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 466
- Registration Number
- NCT03158688
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Baylor Charles A Sammons Cancer Center at Dallas, Dallas, Texas, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 50
- Registration Number
- NCT03141203
- Locations
- 🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
🇬🇧Derriford Hospital, Plymouth, United Kingdom
🇬🇧Southampton General Hospital, Southampton, United Kingdom
Combination Study for High Risk Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT03104270
- Locations
- 🇺🇸
Robert A. Moss, MD, FACP, Inc, Fountain Valley, California, United States
🇺🇸Pacific Cancer Care, Monterey, California, United States
🇺🇸California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
- Conditions
- Interventions
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Target Recruit Count
- 246
- Registration Number
- NCT03104842
- Locations
- 🇩🇪
Vivantes Am Urban, Berlin, Germany
🇩🇪Städt. Kliniken Bielefeld Klinikum Mitte, Bielefeld, Germany
🇩🇪Campus Benjamin Franklin Charite Berlin, Berlin, Germany
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT03031730
- Locations
- 🇺🇸
NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸University of Texas at Austin, Austin, Texas, United States
🇺🇸Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 126
- Registration Number
- NCT03029234
- Locations
- 🇨🇳
Guangzhou First Peoples Hospital, Guangzhou, Guangdong, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳West China Hospital, Sichuang University, Chengdu, Sichuan, China
2015-12: a Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 50
- Registration Number
- NCT03004287
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 359
- Registration Number
- NCT02970747
- Locations
- 🇩🇪
Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 47
- Registration Number
- NCT02969837
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸NorthShore University Health System, Evanston, Illinois, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
High Dose Carfilzomib for Newly Diagnosed Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT02937571
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.